Literature DB >> 31432389

Early Detection of Localized Immunity in Experimental Autoimmune Myocarditis Using [99mTc]Fucoidan SPECT.

Jonathan Vigne1,2,3, Thomas Cognet4, Kevin Guedj4, Marion Morvan4, Olivier Merceron5, Liliane Louedec4, Christine Choqueux4, Antonino Nicoletti4, Brigitte Escoubet4, Frederic Chaubet4, Jean-Baptiste Michel4, François Rouzet4,6,7.   

Abstract

PURPOSE: The aim of the study was to evaluate the ability of technetium-99m-fucoidan ([99mTc]fucoidan), a molecular imaging agent specific for selectins, in the assessment of early localized immunity in a rat model of experimental autoimmune myocarditis (EAM). PROCEDURES: EAM was induced in Lewis rats and troponin T; brain natriuretic peptide (BNP) and anti-myosin antibodies were measured in plasma. Separately, [99mTc]fucoidan single-photon emission computed tomography (SPECT)/x-ray computed tomography (CT) was performed in the very early phase of myocarditis at 10, 15, and 21 days after immunization. Then, hearts were collected and used for autoradiography, well counting, histology, and flow cytometry analysis.
RESULTS: The EAM acute phase is characterized by extensive myocardial necrosis, release of troponin and BNP, and pericardial effusion. [99mTc]Fucoidan uptake was significantly increased in EAM compared with controls starting from D15. There was a close relationship between uptake of the tracer and myocardial content in CD45+, CD8+, CD11b+, and CD31+ cells.
CONCLUSIONS: [99mTc]Fucoidan SPECT/CT accurately diagnosed the autoimmune attack in the early steps of EAM and could be used to monitor disease evolution and therapy efficiency.

Entities:  

Keywords:  CD45+/CD31+; Fucoidan; Molecular imaging; Myocarditis; Scintigraphy; Selectins

Mesh:

Substances:

Year:  2020        PMID: 31432389     DOI: 10.1007/s11307-019-01420-8

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  46 in total

Review 1.  Myocarditis.

Authors:  A M Feldman; D McNamara
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

2.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.

Authors:  R E McCarthy; J P Boehmer; R H Hruban; G M Hutchins; E K Kasper; J M Hare; K L Baughman
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

Review 3.  Myocarditis: current trends in diagnosis and treatment.

Authors:  Jared W Magnani; G William Dec
Journal:  Circulation       Date:  2006-02-14       Impact factor: 29.690

4.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Alida L P Caforio; Sabine Pankuweit; Eloisa Arbustini; Cristina Basso; Juan Gimeno-Blanes; Stephan B Felix; Michael Fu; Tiina Heliö; Stephane Heymans; Roland Jahns; Karin Klingel; Ales Linhart; Bernhard Maisch; William McKenna; Jens Mogensen; Yigal M Pinto; Arsen Ristic; Heinz-Peter Schultheiss; Hubert Seggewiss; Luigi Tavazzi; Gaetano Thiene; Ali Yilmaz; Philippe Charron; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-07-03       Impact factor: 29.983

5.  Myocarditis: the Dallas criteria.

Authors:  H T Aretz
Journal:  Hum Pathol       Date:  1987-06       Impact factor: 3.466

6.  Diagnosis of myocarditis by endomyocardial biopsy.

Authors:  H T Aretz
Journal:  Med Clin North Am       Date:  1986-11       Impact factor: 5.456

7.  Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period.

Authors:  Cristina Chimenti; Andrea Frustaci
Journal:  Circulation       Date:  2013-09-04       Impact factor: 29.690

8.  Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease.

Authors:  Alida L P Caforio; Yehuda Adler; Carlo Agostini; Yannick Allanore; Aris Anastasakis; Michael Arad; Michael Böhm; Philippe Charron; Perry M Elliott; Urs Eriksson; Stephan B Felix; Pablo Garcia-Pavia; Eric Hachulla; Stephane Heymans; Massimo Imazio; Karin Klingel; Renzo Marcolongo; Marco Matucci Cerinic; Antonis Pantazis; Sven Plein; Valeria Poli; Angelos Rigopoulos; Petar Seferovic; Yehuda Shoenfeld; Josè L Zamorano; Ales Linhart
Journal:  Eur Heart J       Date:  2017-09-14       Impact factor: 29.983

9.  Long-term evolution and prognostic stratification of biopsy-proven active myocarditis.

Authors:  Marco Anzini; Marco Merlo; Gastone Sabbadini; Giulia Barbati; Gherardo Finocchiaro; Bruno Pinamonti; Alessandro Salvi; Andrea Perkan; Andrea Di Lenarda; Rossana Bussani; Jozef Bartunek; Gianfranco Sinagra
Journal:  Circulation       Date:  2013-10-01       Impact factor: 29.690

Review 10.  Myocarditis.

Authors:  Gabriel Fung; Honglin Luo; Ye Qiu; Decheng Yang; Bruce McManus
Journal:  Circ Res       Date:  2016-02-05       Impact factor: 17.367

View more
  3 in total

Review 1.  Therapies from Fucoidan: New Developments.

Authors:  Helen J Fitton; Damien S Stringer; Ah Young Park; Samuel N Karpiniec
Journal:  Mar Drugs       Date:  2019-10-09       Impact factor: 5.118

2.  Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases.

Authors:  Cédric Chauvierre; Rachida Aid-Launais; Joël Aerts; Frédéric Chaubet; Murielle Maire; Lucas Chollet; Lydia Rolland; Roberta Bonafé; Silvia Rossi; Simona Bussi; Claudia Cabella; Laszlo Dézsi; Tamas Fülöp; Janos Szebeni; Youssef Chahid; Kang H Zheng; Erik S G Stroes; Dominique Le Guludec; François Rouzet; Didier Letourneur
Journal:  Mar Drugs       Date:  2019-12-12       Impact factor: 5.118

Review 3.  Advances in Radiopharmaceutical Sciences for Vascular Inflammation Imaging: Focus on Clinical Applications.

Authors:  Kevin Prigent; Jonathan Vigne
Journal:  Molecules       Date:  2021-11-24       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.